Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker – 4.2)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 6, November-December, p. 1165–1172

doi: 10.17219/acem/36603

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Polymorphisms of TGFβ1T+869C and C-509T with Lung Cancer Risk: A Meta-analysis

Zhaomin Deng1,A,B,C,D,E,F, Yuan Yang1,A,B,C,D,E,F, Xiaojun Huang1,A,B,C,D,E,F, Yu Kuang1,A,B,C,D,E,F, Zhen Qin1,B,C,D,E,F, Baoning Wang1,B,C,D,E,F, Hongren Wang1,B,C,D,E,F, Mingyuan Li1,A,B,C,D,E,F

1 Department of Microbiology, West China School of Preclinical and Forensic Medicine, Sichuan University

Abstract

Background. Lung cancer is the most common malignancy worldwide. A better understanding of the mechanisms may contribute to early diagnosis and establishment of new therapeutic targets.
Objectives. A meta-analysis was performed to investigate the association of transforming growth factor-beta 1 (TGFβ1) T+869C and C-509T polymorphisms with lung cancer susceptibility.
Material and Methods. Relevant studies were identified through PubMed, Medline, Embase and CNKI databases. The pooled odds ratios (ORs) with its 95% confidence intervals (CIs) were employed to assess these associations in a fixedor random-effects model.
Results. For the TGFβ1 T+869C polymorphism, 5 published case-control studies with 1167 cases and 1365 controls were included. Overall, no significant association was found between the TGFβ1 T+869C polymorphism and lung cancer susceptibility under any genetic models in the total population (p > 0.05). A subgroup analysis by ethnicity showed no significant association among the Asian population as well, while a significant association was observed in Caucasian descendants. For the TGFβ1 C-509T polymorphism, 4 studies were considered, including 1029 cases and 1133 controls. However, this polymorphism also did not increase the risk of lung cancer in all genetic comparison models.
Conclusion. This meta-analysis suggests that TGFβ1 T+869C and C-509T polymorphisms may not contribute to lung cancer risk in the total population, while the T+869C polymorphism may increase the risk of lung cancer in the Caucasian population. However, many studies are still required to evaluate these associations in large populations.

Key words

lung cancer, polymorphism, meta-analysis, transforming growth factor-beta 1

References (46)

  1. The World Cancer Report: The major findings. Cent Eur J Public Health 2002, 11, 177–179.
  2. Wu X, Zhao H, Suk R, Christiani DC: Genetic susceptibility to tobacco-related cancer. Oncogene 2004, 23, 6500– –6523.
  3. Thorgeirsson TE, Geller F, Sulem P: A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008, 452, 638–642.
  4. Hung RJ, McKay JD, Gaborieau V: A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008, 452, 633–637.
  5. Wang Y, Broderick P, Webb E: Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 2008, 40, 1407–1409.
  6. Shimura T, Hagihara M, Takebe K: The study of tumor necrosis factor beta gene polymorphism in lung cancer patients. Cancer 1994, 73, 1184–1188.
  7. Seifart C, Plagens A, Dempfle A: TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers 2005, 21, 157–165.
  8. Huang XF, Chai Y: Molecular regulatory mechanism of tooth root development. Int J Oral Sci 2012, 4, 177–181.
  9. Siegel PM, Massague J: Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2002, 3, 807–821.
  10. Gordon KJ, Blobe GC: Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta 2008, 1782, 197–228.
  11. Dunning AM, Ellis PD, McBride S: A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2002, 63, 2610–2615.
  12. Suthanthiran M, Li B, Song JO: Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci USA 2000, 97, 3479–3484.
  13. Grainger DJ, Heathcote K, Chiano M: Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 1999, 8, 93–97.
  14. Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y: Association of a T29-->C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000, 101, 2783–2787.
  15. Luedecking EK, DeKosky ST, Mehdi H, Ganguli M and Kamboh MI: Analysis of genetic polymorphisms in the transforming growth factor-beta1 gene and the risk of Alzheimer’s disease. Hum Genet 2000, 106, 565–569.
  16. Silverman ES, Palmer LJ, Subramaniam V: Transforming growth factor-beta1 promoter polymorphism C-509T is associated with asthma. Am J Respir Crit Care Med 2004, 169, 214–219.
  17. Saha A, Gupta V, Bairwa NK, Malhotra D and Bamezai R: Transforming growth factor-beta1 genotype in sporadic breast cancer patients from India: Status of enhancer, promoter, 5’-untranslated-region and exon-1 polymorphisms. Eur J Immunogenet 2004, 31, 37–42.
  18. Lau J, Ioannidis JP, Schmid CH: Quantitative synthesis in systematic reviews. Ann Intern Med 1997, 127, 820–826.
  19. Berman NG, Parker RA: Meta-analysis: Neither quick nor easy. BMC Med Res Methodol 2002, 2, 10.
  20. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22, 719–748.
  21. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7, 177–188.
  22. Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315, 629–634.
  23. Bai L, Yu H, Wang H, Su H, Zhao J, Zhao Y: Genetic single-nucleotide polymorphisms of inflammation-related factors associated with risk of lung cancer. Med Oncol 2013, 30, 414.
  24. Teixeira AL, Araujo A, Coelho A: Influence of TGFB1+869T>C functional polymorphism in non-small cell lung cancer (NSCLC) risk. J Cancer Res Clin Oncol 2011, 137, 435–439.
  25. Park KH, Lo Han SG, Whang YM: Single nucleotide polymorphisms of the TGFB1 gene and lung cancer risk in a Korean population. Cancer Genet Cytogenet 2006, 169, 39–44.
  26. Kang HG, Chae MH, Park JM: Polymorphisms in TGF-beta1 gene and the risk of lung cancer. Lung Cancer 2006, 52, 1–7.
  27. Colakogullari M, Ulukaya E, Yilmaztepe Oral A: The involvement of IL-10, IL-6, IFN-gamma, TNF-alpha and TGF-beta gene polymorphisms among Turkish lung cancer patients. Cell Biochem Funct 2008, 26, 283–290.
  28. Li T, Ren J, Ma Y: Correlation of transforming growth factor-β 1 gene –509C/T polymorphism and genetic susceptibility to non-small cell lung cancer in Chinese population. Chinese Journal of Cancer Prevention and Treatment 2012, 19, 410–414.
  29. Woo SU, Park KH, Woo OH: Association of a TGF-beta1 gene -509 C/T polymorphism with breast cancer risk: A meta-analysis. Breast Cancer Res Treat 2010, 124, 481–485.
  30. Saltzman BS, Yamamoto JF, Decker R: Association of genetic variation in the transforming growth factor beta-1 gene with serum levels and risk of colorectal neoplasia. Cancer Res 2008, 68, 1236–1244.
  31. Garcia-Gonzalez MA, Strunk M, Piazuelo E: TGFB1 gene polymorphisms: their relevance in the susceptibility to Helicobacter pylori-related diseases. Genes Immun 2006, 7, 640–646.
  32. Alliston T, Choy L, Ducy P, Karsenty G, Derynck R: TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J 2001, 20, 2254–2272.
  33. Derynck R, Akhurst RJ, Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001, 29, 117–129.
  34. Zhang L, Yang M, Bi N: Association of TGF-beta1 and XPD polymorphisms with severe acute radiation-induced esophageal toxicity in locally advanced lung cancer patients treated with radiotherapy. Radiother Oncol 2010, 97, 19–25.
  35. Cai Q, Tang Y, Zhang M: TGFbeta1 Leu10Pro polymorphism contributes to the development of prostate cancer: Evidence from a meta-analysis. Tumour Biol 2013, 35, 667–673.
  36. Huang Y, Li B, Qian J, Xie J, Yu L: TGF-beta1 29T/C polymorphism and breast cancer risk: A meta-analysis involving 25 996 subjects. Breast Cancer Res Treat 2010, 123, 863–868.
  37. Massague J: TGF beta in cancer. Cell 2008, 134, 215–230.
  38. Adorno M, Cordenonsi M, Montagner M: A mutant-p53/Smad complex opposes p63 to empower TGFbetainduced metastasis. Cell 2009, 137, 87–98.
  39. Watanabe Y, Kinoshita A, Yamada T: A catalog of 106 single-nucleotide polymorphisms (SNPs) and 11 other types of variations in genes for transforming growth factor-beta1 (TGF-beta1) and its signaling pathway. J Hum Genet 2002, 47, 478–483.
  40. Shu XO, Gao YT, Cai Q: Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: A report from the Shanghai Breast Cancer Study. Cancer Res 2004, 64, 836–839.
  41. Crilly A, Hamilton J, Clark CJ, Jardine A, Madhok R: Analysis of transforming growth factor beta1 gene polymorphisms in patients with systemic sclerosis. Ann Rheum Dis 2002, 61, 678–681.
  42. Kim YJ, Lee HS, Im JP: Association of transforming growth factor-beta1 gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Exp Mol Med 2003, 35, 196–202.
  43. Wei BB, Xi B, Wang R: TGFβ1 T29C polymorphism and cancer risk: A meta-analysis based on 40 case-control studies. Cancer Genet Cytogenet 2010, 196, 68–75.
  44. Liu Y, Lin XF, Lin CJ, Jin SS, Wu JM: Transforming growth factor beta-1 C-509T polymorphism and cancer risk: A meta-analysis of 55 case-control studies. Asian Pac J Cancer Prev 2012, 13, 4683–4688.
  45. Hou YL, Chen H, Dong ZH: Clinical significance of serum transforming growth factor-β1 in lung cancer. Cancer Epidemiol 2013, 37, 750–753.
  46. He J, Deng L, Na F, Xue J, Gao H, Lu Y: The association between TGF-β1 polymorphisms and radiation pneumonia in lung cancer patients treated with definitive radiotherapy: A meta-analysis. PLoS One 2014, 9, e91100.
© Wroclaw Medical University